| |
|
|
| |
 |
|
|
|
|
|
Co-infection with hepatitis among people with HIV is emerging as a growing problem. For people infected with HIV through needle exposure probably due to drug use, 40% or more may also have hepatitis C. The NATAP Hepatitis Section was started to raise awareness about this problem, and to provide basic education and more advanced scientific information.
If you have HIV you should speak to your doctor about testing for hepatitis A, B, and C. A person with hepatitis C may progress more quickly if they contract hepatitis A. If you have hepatitis C, but don't have hepatitis A, it's advisable to consider getting the hepatitis A vaccine.
As we report important information from key AIDS conferences, NATAP will be reporting important information presented at key hepatitis scientific conferences. They are posted below. Treatment guidelines presented by the European Association for The Study of Liver Disease at a consensus conference are posted below. NATAP will also be reporting new information from future key hepatitis conferences.
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
| |
| |
HEPATITIS C and HCV/HIV COINFECTION
The lastest update on Hepatitis and HIV and HCV Coinfection. -epidemiology, the most current study results on treatment and side effects, who should be treated, and new drugs.
Monitor Your Liver Health in People with Chronic HCV
The Checkup, The Lab Work, Blood Platelet Count, Liver Enzyme Levels,
Alpha-Fetoprotein Level, Liver Biops.
Current Review on Hepatitis C Virus in HIV/HCV Coinfection
Written for NATAP by Andrew Talal, M.D., and Ira Jacobson, M.D. (6/11/2001)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CLINICAL TRIAL HOTLINE
Pegasys Clinical Trials Hotline Telephone Number
People with HCV or HIV/HCV can get information about Pegasys clinical trials in their area by calling (866) GO-WINGS. Callers are connected to a live person who can refer them to clinical trial sites in their area based on their sero-status. It is up to the caller to contact the sites to make an appointment to be screened
|
|
| |
|
|
|
|
IMPACT OF PREGNANCIES, ORAL CONTRACEPTION AND MENOPAUSE ON LIVER FIBROSIS PROGRESSION IN WOMEN WITH CHRONIC HEPATITIS C
(12/3/01)
|
HCV Therapy Adherence; New drugs
(12/3/01)
|
Treatment of Acute Hepatitis C with Interferon Alfa-2b
(10/01/01)
|
Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study
(10/01/01)
|
Glycyrrhizin-induced reduction of ALT in European patients with chronic hepatitis C
(9/28/01)
|
Transplantation of hepatitis C-positive livers in hepatitis C-positive patients is equivalent to transplanting hepatitis C-negative livers
(9/28/01)
|
Factors
Affecting Liver Fibrosis in Human Immunodeficiency Virus and
Hepatitis C Virus Coinfected Patients: Impact of Protease Inhibitor
Therapy
(9/24/01)
|
Peginterferon
alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin
for initial treatment of chronic hepatitis C: a randomised trial
(9/240/01)
|
Mother-to-Infant
Transmission of Hepatitis C Virus
with full
version in PDF
format
(9/14/01)
|
A
Randomized, Double-Blind Trial Comparing Pegylated Interferon Alfa-2b
to Interferon Alfa-2b as Initial Treatment for Chronic Hepatitis C
with full
version in PDF
format
(9/13/01)
|
Safety
and efficacy of oral entecavir given for 28 days in patients with chronic
hepatitis B virus infection
(9/10/01)
|
Viral
Load at Week 12 and Reduction in Viral Load in First 12 weeks of Therapy
is Useful in Predicting Response
with complete report in
PDF
(9/6/01)
|
Development
of Pegylated Interferons for the Treatment of Chronic Hepatitis C
in PDF
format only
(9/4/01)
|
Can
Cirrhotics Achieve a Histologic Response?
with PDF
of full article
(9/4/01)
|
Can
HCV Be Cured: more on longterm outcomes in Sustained Virologic Responders
(8/16/01)
|
Hepatitis
B Update
Adefovir
for HBV ...>
Safety
& Adefovir Resistance
...>
Adefovir
30mg Dose: safety concerns
...>
Adefovir
plus HAART shows benefits for HIV/HBV co-infected patients
...>
3TC
Resistance: incidence in HBV and HIV/HBV treatment
...>
Adefovir
10 mg Added to HAART with 3TC HBV Resistance
...>
Week
48 Interim Results
...>
Entecavir:
new Hepatitis B drug in early research
...>
L-DT:
New Hepatitis B Drug
...>
(8/5/01)
|
HIV
Patients Getting More Transplants
By
DENISE LAVOIE, Associated Press Writer
(8/5/01)
|
Evidence
for a cerebral effect of the hepatitis C virus
(8/5/01)
|
10-Year
Follow-up After Interferon- Therapy for Chronic Hepatitis C: all 5 patients
with sustained viral response remained HCV-RNA negative by liver biopsy
(8/3/01)
|
Predictive
Value of Alt Levels On Histological Findings In Chronic Hepatitis C:
A European Collaborative Study
(8/2/01)
|
Independent
Predictors of Severe Liver Fibrosis in Chronic Hepatitis C
(8/2/01)
|
HCV
& Pregnancy, risk factors for transmission: breastfeeding, c-section,
use of forceps in delivery
(8/1/01)
|
Impact
of Hiv Infection On Health-Related Quality of Life In Patients with Chronic
Hepatitis C: An Unexpected Finding
(8/1/01)
|
High
Dose Induction Therapy With Consensus Interferon Followed By Combination
Therapy With Ribavirin For Treatment-Naive Hepatitis C Patients
(8/1/01)
|
Diet
and Hepatitis C
Written for NATAP by Jocelyn Rodriguez
(8/1/01)
|
Does
HAART Affect Liver Disease Progression in HCV/HIV Coinfected Patients?
(7/11/01)
|
Assessment
of Fatigue and Psychologic Disturbances in Patients with Hepatitis C
Virus Infection
with
PDF of full article
(7/9/01)
|
Patient's
Ability to Mount an Immune Response Appears Associated with Response
to HCV Therapy
(7/9/01)
|
Preliminary
study Results Show HCV in Blood Reflects HCV in Liver Cells
(7/9/01)
|
Transplantation
in HIV-positive Patients?
Latest
update from University of Pittsburgh, from John Fung, MD, PhD, 06/28/01
(7/9/2001)
|
Study
of Treatment for HCV Following Recurrence of HCV After Liver Transplant
(7/9/2001)
|
Predicting
Response to HCV Therapy After One Day of Inteferon
(7/9/2001)
|
Two
Studies Find Benefit in Treating HCV During Acute Infection
(7/9/2001)
|
Hepatitis
C: current & future treatment, progress & challenges
(7/9/2001)
|
Molecular
Biology of Hepatitis C
Full
Article in PDF
format...>
written
by Kenneth Drazan, MD
(6/25/2001)
|
The impact of HIV
infection on the hepatitis B (HBV)-specific CD8 response in HIV/HBV
coinfected patients
(5/14/2001)
|
Sexual Risk of HCV
Transmission
Hepatitis
C virus among high and low risk pregnant women in Dundee: unlinked anonymous
testing: another study suggesting sexual risk of transmitting HCV
(5/09/2001)
|
Effects of mode of delivery
and infant feeding on the risk of mother-to-child transmission of hepatitis
C virus
European Paediatric Hepatitis C Virus Network
(5/08/2001)
|
Amantadine+Interferon/Ribivarin
in Interferon Non-Responders
Randomized,
Controlled Trial with Interferon-Alpha (IFN-ALPHA) Combined with
Ribavirin, With and Without Amantadine Sulfate in Primary IFN-Alpha
Nonresponsive Patients with Chronic Hepatitis C
(5/07/2001)
|
Durability of
Sustained Virologic Response: 3 year follow-up
Durability of Viral Response to Interferon Ribavirin Combination in
Patients with Chronic Hepatitis C: of 311 SVRs, during 3 years follow-up
7 patients had late relapse
(5/07/2001)
|
Entecavir: new
Hepatitis B drug in early research
A Phase II Study
of Entecavir vs. Lamivudine in Adulst with Chronic Hepatitis B
(5/07/01)
|
Assessment of Fatigue
and Psychologic Disturbances in Patients with Hepatitis C Virus Infection
Gastroenterol, May 2001
(5/07/2001)
|
New Ribivarin in Research (ICN 17261)
(5/07/2001)
|
More on Amantadine
in Combination with Interferon and Ribivarin
(5/06/2001)
|
Highlights from
The 36th Annual Meeting of EASL
(European Association for the Study of the Liver) April 18-22, 2001,
Prague, Czech Republic
Written
for NATAP by Harvey S. Bartnof, MD
(4/21/2001)
|
Maintenance interferon for
chronic hepatitis C: More issues than answers?
Written
by Gregory T. Everson, M.D.
(Full PDF
of this article)
(4/30/2001)
|
Virologic Response To Pegasys With Genotype 4 in Small
Study Group
(4/10/2001)
|
Human Genome Sciences To Test New Delivery Method for HCV
Interferon
By Scott Henley of the Wall St. Journal
/ Help
(3/25/2001)
|
Check Your Thyroid
Function Before & During Interferon Therapy:
Interferon-alpha-induced disorders of thyroid function. A retrospective
analysis of the literature and personal experiences
(3/11/2001)
|
Hepatitis
Virus Infections, Including HIV Co-Infection Part III:
6%-20%
of HCV/HIV coinfected found to have false HCV negativity, may be related
to low CD4 count; HBV false negatives also seen
By Harvey S. Bartnof, MD
(3/01/2001)
|
This report
finds high HCV viral load increases risk of transmission of HCV from
mother to newborn
HCV Viremia
at Delivery a Risk Factor for Mother-to-Infant Transmission
WESTPORT, CT (Reuters Health)
(2/26/2001)
|
NOTICE TO ADVOCACY GROUPS:
Pegasys HCV/HIV Coinfection Study for HCV Interferon &
Ribivarin Naive
You may be eligible to participate in this study if you:
Are coinfected with HCV (hepatitis C virus)
and HIV
Are 18 years or older
(2/7/2001)
|
Interferon Appears to Slow Progression,
cancer & death in this Japanese Study of Patients with Compensated
Cirrhosis
Prevention
of hepatocellular carcinoma in patients with chronic active hepatitis
C and cirrhosis
with PDF of entire article
(1/31/2001)
|
Biopsy Is Required To Evaluate Liver
Disease Severity and Decide When To Begin Therapy
The Histologic Spectrum
of Chronic Hepatitis C in Patients with Repeatedly Normal ALT (Alanine
Aminotransferase): Does Liver Biopsy Make a Difference?
(1/28/2001)
|
Pharmacokinetics
on Two Pegylated Interferons Reported at AASLD 1999 (2/23/2000)
|
Peg Intron
FDA Approved
First Pegylated Interferon Approved
for Marketing in the United States
Schering Press Release
|
FDA Approves
Hepatitis C Therapy: Peg Intron Pricing
By THE ASSOCIATED PRESS
(01/24/2001)
|
Age-related response
to interferon alfa treatment in women vs men with chronic hepatitis
C virus infection: women 39 years or less of age respond better
to HCV treatment than men and women older than 40 years
Department
of General Medicine, Kyushu University Hospital,
Fukuoka, Japan.
Archives of Internal Medicine. 158(2):177-81,
1998 Jan 26
(01/24/2001)
|
AASLD Report
On HCV Therapy
Toxicities
Hemoglobin
Decreases from Combination HCV Therapy including Ribibarin (01/08/2001)
|
Three
Factors Predictive of ALT > 5 times Upper Limit of Normal: HBV, HCV
and elevated baseline ALT; 45% with HBV & 33% with HCV had ALT >
5 times Upper limit of Normal (01/03/2001)
|
Interferon-alpha
induced thyroid dysfunction: three clinical presentations and a review
of the literature (01/02/2001)
|
Fatigue Affecting
People With Liver Disease (01/01/2001)
|
